Patient Power: Too Much of a Good Thing?
November 22, 2013 | Crohn's Disease, Market tracking, Patient Understanding, Patient insights, patient behaviour
Mary Assimakopoulos, reveals findings from the company’s Therapy Watch market research data, investigating patient behaviour in Crohn’s Disease and discusses how pharma can benefit from improved patient understanding
In an earlier column I discussed the issue of non-adherence in diabetes and proposed that a better understanding of patient behaviour may improve compliance. In this column, I’m going to be looking at Crohn’s Disease and asking if too much patient power is always a good thing.
Crohn’s disease is a form of Inflammatory Bowel Disease that can affect any part of the gastrointestinal tract and has a wide range of symptoms. It commonly causes abdominal pain, diarrhoea, weight loss and vomiting but because it affects the immune system it can cause other problems such as anaemia, arthritis, lack of concentration, tiredness and inflammation of the eye.
The Research Partnership conducts a regular tracking research study amongst physicians treating patients with Crohn’s disease in Europe and the USA. Data from this research reveals that surprisingly, despite how much it can affect day-to-day living, a proportion of patients are actively refusing biologic treatment.
According to our study, nineteen percent of patients in the US and nine percent of patients in the EU who are being offered a biologic are refusing to take it, largely because of concerns about side effects. A proportion, around one third of American and one quarter of Europeans, also express fear over self-injection / IV infusion.
Around 700,000 Europeans are diagnosed with Crohn’s disease each year. There is no known cure and, if severe, it can be very hard to live with. Some patients are successful at managing their disease with a controlled diet. A young patient with Crohn’s describes her symptoms on support website www.meandibd.org: “Before diagnosis I lost 3 dress sizes and bled continuously. It took a while to be diagnosed, although I’d had symptoms since around the age of 14. I was off school a lot. People thought I was lazy as I felt so exhausted I couldn’t do anything.”
Most treatments such as steroids will only help to reduce the symptoms. There are currently only two biologic treatments available to patients, Humira and Remicade, which are employed to bring patients with moderate to severe Crohn’s to a state of remission. In extreme cases patients can opt to have surgery, but as this involves removing large parts of the colon, physicians prefer non-interventional options and will only recommend this as a last resort.
What more can be done to appropriately manage patients’ fears to get them on these more effective treatments? Why do some patients accept the (small) risks and others can’t get past them?
Other findings from the survey suggest that patients do eventually “give in” and accept biologics, despite their initial fears, but at what cost to their overall health? Our data reveals that around a third of all current biologic patients in EU and US could have been treated earlier. Almost half (42%) of patients in the US and a quarter of patients in Europe had their biologic treatment delayed because the patient had refused to take the biologic up to that point. It takes between 3-5 years from presentation for a patient to be diagnosed with Crohn’s and the earlier the patient is treated, the better the outcome. Have the short-term fears of the patient sometimes become too powerful, at the expense of the individual’s longer-term health needs?
Therapy Watch found that whilst discontinuation rates are generally low with biologics, there is a small cohort of patients – around 8% – who elect to stop their own treatment, although we don’t know whether this is because they believe that their disease has improved or whether they are experiencing strong side effects. It would seem that the biggest challenge for the healthcare industry is getting patients to accept biologic treatment rather than persuading them to stick with it.
Can too much patient power be a bad thing for patient outcomes? Maybe not, provided the patient is well informed and educated about their treatment options and their benefits. According to our survey, around three times the number of US patients (17%) versus EU patients (6%) actively asked to be put on a biologic. This may be a response to direct-to-consumer advertising, which is only legal in the USA. Are US patients more informed about treatment options? In which case, is patient education the way to improve patient outcomes? Something for the pharma brands to ponder….One thing is for certain, patients who are refusing biologic treatment need to be better informed. Perhaps a deeper understanding of patients’ needs will give further insight into why this group of patients are refusing treatment and reveal ways of changing perceptions and behaviour.
Published Sep 10, 2013 eyeforpharma.com
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more at http://bit.ly/1euM10E
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
Case Study: Oncology diagnostic biomarker landscaping study
The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...
Research Partnership publishes 2016 Living with RA reports
Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.
Article: The Art of Storytelling in Pharma Market Research
Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director
Video: Immuno-oncology therapies
Immuno-oncology therapies which harness the body’s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. However, these therapies come with a very high price...
The challenges of conducting effective pharmaceutical market research in emerging markets
Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets
Research Partnership appoints Director and Head of Business Analytics, North America
Tom has been appointed a Director in our Philadelphia office. He has over 25 years’ experience in healthcare research and has an extensive background in both quantitative and qualitative research,...
Article: The Art of Storytelling in Pharma Market Research
Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director
Event: EphMRA Annual Conference 2016
Frankfurt, Germany 21 - 23 June 2016
The challenges of conducting effective pharmaceutical market research in emerging markets
Published in Quirk's Marketing Research Review, April 2016, By Marc Yates, Director of Emerging Markets
Blog: Viewing facility research, re-imagined
As technology has evolved, so too has the world of qualitative research